Literature DB >> 23183152

Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial.

Richard E Haaland, Thanyanan Chaowanachan, Tammy Evans-Strickfaden, Janneke H van de Wijgert, Peter H Kilmarx, Catherine A McLean, Clyde E Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183152      PMCID： PMC5549010          DOI： 10.1097/QAI.0b013e318271c8f9

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  12 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  HIV preexposure prophylaxis: new data and potential use.

Authors:  Connie L Celum
Journal:  Top Antivir Med       Date:  2011-12

3.  Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Authors:  Lut Van Damme; Roshini Govinden; Florence M Mirembe; Fernand Guédou; Suniti Solomon; Marissa L Becker; B S Pradeep; A K Krishnan; Michel Alary; Bina Pande; Gita Ramjee; Jennifer Deese; Tania Crucitti; Doug Taylor
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

4.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  Stephanie Skoler-Karpoff; Gita Ramjee; Khatija Ahmed; Lydia Altini; Marlena Gehret Plagianos; Barbara Friedland; Sumen Govender; Alana De Kock; Nazira Cassim; Thesla Palanee; Gregory Dozier; Robin Maguire; Pekka Lahteenmaki
Journal:  Lancet       Date:  2008-12-06       Impact factor: 79.321

5.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

6.  Colorimetric micromethod for protein determination with erythrosin B.

Authors:  H S Soedjak
Journal:  Anal Biochem       Date:  1994-07       Impact factor: 3.365

7.  HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand.

Authors:  Catherine A McLean; Janneke Hhm van de Wijgert; Heidi E Jones; John M Karon; Janet M McNicoll; Sara J Whitehead; Sarah Braunstein; Jullapong Achalapong; Supaporn Chaikummao; Jordan W Tappero; Lauri E Markowitz; Peter H Kilmarx
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

8.  Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.

Authors:  Sara J Whitehead; Catherine McLean; Supaporn Chaikummao; Sarah Braunstein; Wat Utaivoravit; Janneke H van de Wijgert; Philip A Mock; Taweesap Siraprapasiri; Barbara A Friedland; Peter H Kilmarx; Lauri E Markowitz
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

9.  Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.

Authors:  A Robert Neurath; Nathan Strick; Yun-Yao Li
Journal:  BMC Infect Dis       Date:  2006-10-16       Impact factor: 3.090

10.  Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Authors:  Marla J Keller; Pedro M M Mesquita; N Merna Torres; Sylvia Cho; Gail Shust; Rebecca P Madan; Hillel W Cohen; Julie Petrie; Tara Ford; Lydia Soto-Torres; Albert T Profy; Betsy C Herold
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240
View more
  3 in total

1.  In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Authors:  Aixa Rodríguez; Kyle Kleinbeck; Olga Mizenina; Larisa Kizima; Keith Levendosky; Ninochka Jean-Pierre; Guillermo Villegas; Brian E Ford; Michael L Cooney; Natalia Teleshova; Melissa Robbiani; Betsy C Herold; Thomas Zydowsky; José A Fernández Romero
Journal:  Antiviral Res       Date:  2014-06-05       Impact factor: 5.970

2.  Influence of the Structural Features of Carrageenans from Red Algae of the Far Eastern Seas on Their Antiviral Properties.

Authors:  Natalia V Krylova; Anna O Kravchenko; Olga V Iunikhina; Anastasia B Pott; Galina N Likhatskaya; Aleksandra V Volod'ko; Tatyana S Zaporozhets; Mikhail Y Shchelkanov; Irina M Yermak
Journal:  Mar Drugs       Date:  2022-01-08       Impact factor: 5.118

3.  Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.

Authors:  Natalia Teleshova; Marla J Keller; José A Fernández Romero; Barbara A Friedland; George W Creasy; Marlena G Plagianos; Laurie Ray; Patrick Barnable; Larisa Kizima; Aixa Rodriguez; Nadjet Cornejal; Claudia Melo; Gearoff Cruz Rodriguez; Sampurna Mukhopadhyay; Giulia Calenda; Shweta U Sinkar; Thierry Bonnaire; Asa Wesenberg; Shimin Zhang; Kyle Kleinbeck; Kenneth Palmer; Mohcine Alami; Barry R O'Keefe; Patrick Gillevet; Hong Hur; Yupu Liang; Gabriela Santone; Raina N Fichorova; Tamara Kalir; Thomas M Zydowsky
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.